![]() Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S (2007) Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Res 66(7):3381–3385Ĭhawla A, Philips AV, Alatrash G, Mittendorf E (2014) Immune checkpoints: a therapeutic target in triple negative breast cancer. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Gettinger S, Herbst RS (2014) B7-H1/PD-1 blockade therapy in non–small cell lung cancer: current status and future direction. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Hasanzadeh M, Shadjou N (2017) Advanced nanomaterials for use in electrochemical and optical immunoassays of carcinoembryonic antigen. Shan J, Ma Z (2017) A review on amperometric immunoassays for tumor markers based on the use of hybrid materials consisting of conducting polymers and noble metal nanomaterials.
0 Comments
Leave a Reply. |